GNRH1 and prostate carcinoma: For locally advanced prostate cancer, we are developing formulations of LHRH agonists with a very short half-life, encapsulated within species of capsules that have different dissolving times, so that LHRH is released in a cyclic manner every several days, so all or most of the radiation course could be delivered during sequential cycles of testosterone flare (Figure 6).